1. Introduction {#sec1}
===============

Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (*Mtb*) infection, remains one of the top ten causes of death in the world \[[@B1]\]. Approximately one-fourth of the world population has been infected with *Mtb* \[[@B2]\], but only 10% of these infected persons develop progressive disease during their lifetimes \[[@B3]\]. The majority of infected individuals remain healthy and noninfectious but carry *Mtb* in a latent form. Latent TB infection (LTBI) is a state during which a persistent host immune response to stimulation by *Mtb* antigens is sustained without evidence of clinically manifested active TB \[[@B4], [@B5]\]. As many as 10% of people with LTBI will go on to develop progressive disease in the near or remote future (a process named "TB reactivation"), and the risk is significantly higher in the presence of predisposing factors, such as coinfection with human immunodeficiency virus (HIV).

Persons with LTBI can be diagnosed by skin (tuberculin skin test (TST)) and/or blood (interferon-gamma (IFN*γ*) release assay (IGRA)) tests \[[@B6]\]. A positive result from these assays indicates an immune response to stimulation by *Mtb* antigens in the LTBI population, despite the fact that these individuals have a negative bacteriological test. However, neither TST nor IGRA can distinguish between LTBI and active TB disease or predict who will progress to active TB \[[@B7]\]. Given that the LTBI individuals represent a potential reservoir for future active TB cases, preventive therapy for LTBI is as important a goal as timely anti-TB treatment to reduce the burden of TB \[[@B8]\]. Therefore, identifying and treating cases with LTBI will contribute to TB elimination. Fundamental research for the development of diagnostic assays with improved performance and predictive assessment for TB reactivation will have practical applications and offer a substantial benefit for LTBI management.

In both humans and experimental animal models, genetic polymorphisms among hosts have been shown to contribute to the outcome of *Mtb* infection \[[@B9]--[@B13]\]. In mice, the *Ipr1* (intracellular pathogen resistance 1) gene is located within the *sst1* (supersusceptibility to tuberculosis 1) locus on chromosome 1 (49-54 cM) \[[@B14]\] and has been identified as a genetic determinant conferring host innate immunity to *Mtb* infection \[[@B15]\]. The previous studies indicate that the *Ipr1* gene may function to integrate mechanisms on controlling cell death, innate immunity, and pathogenesis during intracellular pathogen infections \[[@B15], [@B16]\]. The gene orthologous to the mouse *Ipr1* in humans is *SP110*, located on chromosome 2q37.1. Expression of both *Ipr1* and *SP110* genes is intensively regulated by IFNs, suggesting that the function of both genes is related to the IFN-mediated immune response \[[@B17]\].

Genetic defects in the *SP110* gene have been found to be responsible for hepatic veno-occlusive disease and immunodeficiency \[[@B18], [@B19]\], indicating that the gene plays important roles in immunity \[[@B20]\]. The *SP110* gene encodes the SP110 nuclear body protein, which has at least three isoforms, including the dominantly expressed SP110a, b, and c isoforms that are believed to be the result of alternative mRNA splicing. Our recent study demonstrated that SP110b, which is most similar to mouse Ipr1 and is expressed more abundantly than SP110a and SP110c, modulates nuclear factor-*κ*B (NF-*κ*B) activity resulting in the downregulation of tumor necrosis factor-*α* (TNF*α*) production and concomitant upregulation of NF-*κ*B-induced antiapoptotic gene expression, thereby suppressing IFN*γ*-mediated monocyte/macrophage cell death \[[@B21]\]. This indicates that the protein is crucial in the control of the activation of macrophages, the reservoir for *Mtb* persistence.

Although a number of genetic variants of the *SP110* gene have been reported to be associated with susceptibility to human TB, the results of studies regarding the relationship between *SP110* polymorphisms and TB susceptibility are inconsistent \[[@B22]--[@B29]\]. A family-based study in West Africa identified 3 *SP110* polymorphisms that are associated with TB susceptibility \[[@B22]\]; however, no significant associations between SP110 and disease susceptibility were identified by other, larger case-control studies conducted on various populations \[[@B24]--[@B26]\]. After screening Taiwanese populations for polymorphisms in *SP110*, we identified some single-nucleotide polymorphisms (SNPs) in *SP110* that are significantly associated with susceptibility to LTBI as well as TB disease. These results suggest that the *SP110* variants may provide novel predictive markers for TB infection status and disease outcome.

2. Materials and Methods {#sec2}
========================

2.1. Human Subject Study {#sec2.1}
------------------------

The study was conducted in accordance with the terms of the informed consent that was provided to, and received from, participants prior to inclusion in the study. This study was approved by the National Taiwan University Hospital Institutional Review Board (IRB No. 200612009M and IRB No. 201512169RINA). Human blood was ethically collected from patients with culture-confirmed pulmonary TB and their household contacts as described previously \[[@B30]\]. Briefly, the participating contacts received chest radiography, and mycobacteriology studies were conducted for 3 sputum samples (including acid-fast smear and mycobacterial culture) to exclude the possibility of active TB disease. Because routine BCG vaccination for newborns in Taiwan could affect the accuracy of tuberculin skin test, all enrolled contacts were then tested for LTBI using a T-SPOT.*TB* assay (Oxford Immunotec Ltd., Abingdon, UK) or QuantiFERON-TB Gold In-Tube assay (QFT) (Qiagen, Hilden, Germany), and the assays were interpreted according to the manufacturers\' criteria. Both patients and contacts were excluded if they were tested positive for HIV infection. In total, 301 pulmonary TB patients, 68 individuals with LTBI, and 278 healthy household contacts were included in the study, and genomic DNA was extracted from their peripheral blood (1-2 mL) using a kit from Qiagen according to the manufacturer\'s protocol. *SP110* polymorphisms were identified from the National Center for Biotechnology Information dbSNP database (<https://www.ncbi.nlm.nih.gov/snp>). The SNPs were genotyped using the MassARRAY System (Sequenom, San Diego, CA, US), and the primer extension products were analyzed by MALDI-TOF mass spectrometry as previously described \[[@B31], [@B32]\]. Details of the primers that were used are listed in [Table S1](#supplementary-material-1){ref-type="supplementary-material"} in the Supplementary Materials.

Plasma samples were prepared from blood samples by centrifugation and then stored at −80°C until analysis. The TNF*α* levels in plasma samples were determined by a MAGPIX® platform (Luminex Corp., Austin, TX. US) with a MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel I kit (Merck Millipore, Billerica, MA, US) according to the manufacturer\'s instructions.

2.2. Statistical Analyses {#sec2.2}
-------------------------

The associations of gene polymorphisms with LTBI and TB disease were analyzed by SAS 9.4 software (SAS Institute, Cary, NC, US) \[[@B33]\]. Linkage disequilibrium and haplotype analyses were performed using Haploview (<https://www.broadinstitute.org/haploview>) \[[@B34]\]. Chi-square tests were used to compare frequencies. Odds ratios (ORs) were calculated with 95% confidence intervals (CIs). Bonferroni correction or false discovery rate (FDR) correction was applied for multiple comparison adjustments as indicated. The difference of the TNF*α* levels in plasma between two genotype groups of samples was calculated using a two-tailed unpaired *t*-test with Prism software (GraphPad, San Diego, CA, US). *p* values less than 0.05 were considered to indicate statistical significance, and the number of asterisks represents the degree of significance with regard to the *p* values.

3. Results {#sec3}
==========

3.1. Association of Polymorphisms in *SP110* with LTBI and TB Susceptibility {#sec3.1}
----------------------------------------------------------------------------

To investigate the association between the *SP110* gene and control of *Mtb* infection, we examined polymorphisms in the gene of members of the Taiwanese population for genetic association with TB disease status. In this study, 301 pulmonary TB patients (202 males and 99 females; mean age: 63.1 ± 19.9 years), 68 individuals with LTBI (35 males and 33 females; mean age: 46.9 ± 17.7 years), and 278 healthy household contacts of the patients (92 males and 186 females; mean age: 47.1 ± 17.3 years) were included ([Table 1](#tab1){ref-type="table"}). In total, 20 SNPs in the SP110 gene were selected for analysis. Of these, 10 SNPs that were not polymorphic or had a minor allele frequency less than 1% were not further included in the analysis, and the remaining 10 SNPs were then analyzed. We found that 3 SNPs (rs7580912, *p* = 0.0426, OR: 1.52, 95% CI: 1.01--2.39; rs7580900, *p* = 0.008, OR: 1.68, 95% CI: 1.14--2.48; and rs9061, *p* = 0.0026, OR: 0.39, 95% CI: 0.21--0.73) showed differential allele frequency distributions in LTBI cases vs. healthy controls ([Table 2](#tab2){ref-type="table"}). After Bonferroni correction, rs9061 remained significant in this analysis (*p* \< 0.05). Although allele frequencies of none of the 10 SNPs differed significantly in TB patients vs. healthy controls ([Table 2](#tab2){ref-type="table"}), 3 SNPs (rs7580900, *p* = 0.0319, OR: 0.66, 95% CI: 0.45--0.97; rs9061, *p* = 0.0116, OR: 2.21, 95% CI: 1.18--4.15; and rs2241525, *p* = 0.0309, OR: 0.6, 95% CI: 0.38--0.96) exhibited differential allele frequency distributions in TB cases vs. LTBI individuals ([Table 2](#tab2){ref-type="table"}). All of these SNPs were in accordance with the Hardy-Weinberg equilibrium (HWE).

The associations between *SP110* genotypes and susceptibility to LTBI and TB were then analyzed. In LTBI cases vs. healthy controls, we found that genotypes "GG" in rs7580912 (*p* = 0.025, OR: 2.451, 95% CI: 1.12--5.364) and "GG" in rs7580900 (*p* = 0.015, OR: 2.584, 95% CI: 1.208--5.53) were associated with LTBI risk and that genotype "GA" in rs9061 exhibited a protective effect on LTBI (*p* = 0.044, OR: 0.494, 95% CI: 0.239--0.981) ([Table 3](#tab3){ref-type="table"}). We also found that genotypes "GG" in rs7580912 (*p* = 0.02, OR: 0.392, 95% CI: 0.179--0.86) and "GG" in rs7580900 (*p* = 0.017, OR: 0.392, 95% CI: 0.182--0.848) in TB patients vs. LTBI cases ([Table 3](#tab3){ref-type="table"}), as well as "CT" in rs11556887 (*p* = 0.039, OR: 0.626, 95% CI: 0.401--0.976) in TB patients vs. healthy controls had a protective effect on TB ([Table 3](#tab3){ref-type="table"}). These results indicated that several SNPs (rs7580900, rs7580912, rs9061, and rs11556887) in *SP110* were associated with susceptibility to LTBI and/or TB disease.

3.2. Association Analyses in Various Inheritance Models {#sec3.2}
-------------------------------------------------------

The minor allele of each SNP was presumed as a risk factor compared to the major allele, and the associations between SNPs and susceptibility to LTBI and TB were analyzed in various inheritance models ([Table 4](#tab4){ref-type="table"}). We found that in LTBI cases vs. healthy controls, rs9061 showed a protective effect on LTBI in both additive (*p* = 0.0059, OR: 0.41, 95% CI: 0.22--0.78) and dominant (*p* = 0.0112, OR: 0.42, 95% CI: 0.21--0.82) models, while rs7580900 was associated with LTBI risk in both additive (*p* = 0.0147, OR: 1.62, 95% CI: 1.1--2.39) and recessive (*p* = 0.0195, OR: 2.13, 95% CI: 1.13--4.03) models. In addition to this finding, rs7580912 was also associated with LTBI risk in a recessive model (*p* = 0.0142, OR: 2.49, 95% CI: 1.2--5.18). In TB patients vs. LTBI cases, rs9061 was associated with TB risk in both additive (*p* = 0.015, OR: 2.17, 95% CI: 1.16--4.06) and dominant (*p* = 0.0273, OR: 2.14, 95% CI: 1.09--4.22) models, while rs7580900 exhibited a protective effect on TB in both additive (*p* = 0.0261, OR: 0.64, 95% CI: 0.43--0.95) and recessive (*p* = 0.0117, OR: 0.45, 95% CI: 0.24--0.84) models and rs2241525 was associated with protection from TB in both additive (*p* = 0.0407, OR: 0.62, 95% CI: 0.4--0.98) and dominant (*p* = 0.0389, OR: 0.55, 95% CI: 0.31--0.97) models. Additionally, rs7580912 had a protective effect on TB in a recessive model (*p* = 0.0043, OR: 0.35, 95% CI: 0.17--0.72). After false discovery rate (FDR) correction, rs7580900 and rs7580912 remained significant (*p* = 0.041 and 0.0301, respectively) in a recessive model in this analysis.

3.3. Linkage Disequilibrium and Haplotype Analyses {#sec3.3}
--------------------------------------------------

We then examined linkage disequilibrium (LD) with the SNP markers in the *SP110* gene using a Haploview analysis. We found that the "ATATACGCGG" and "ATGTACGCGA" haplotypes met statistical significance (*p* = 0.0193, OR: 2.11, 95% CI: 1.11--3.99 and *p* = 0.0225, OR: 2.76, 95% CI: 1.12--6.84, respectively) for association with LTBI risk in LTBI cases vs. healthy controls (see [Figure S1](#supplementary-material-1){ref-type="supplementary-material"} in the Supplementary Materials) and that the "ATGTACGCGA" and "ATGAAAGCGA" haplotypes were statistically significant (*p* = 0.03, OR: 0.38, 95% CI: 0.16--0.95 and *p* = 0.0324, OR: 0.24, 95% CI: 0.06--0.99, respectively) with a protective effect on TB in TB cases vs. LTBI individuals (see [Figure S2](#supplementary-material-1){ref-type="supplementary-material"} in the Supplementary Materials). Interestingly, the "GCGTACGCGG" haplotype was associated with TB risk (*p* = 0.0169, OR: 3.81, 95% CI: 1.18--12.31) in TB cases vs. healthy controls (see [Figure S3](#supplementary-material-1){ref-type="supplementary-material"} in the Supplementary Materials), although none of the SNPs studied show a significant difference in frequency distributions in this comparison ([Table 2](#tab2){ref-type="table"}). Noteworthily, when we compared "ATGTACGCAA" (the most frequent haplotype) with "ATGTACGCGA" (the haplotype that was associated with LTBI risk in LTBI cases vs. healthy controls and had a protective effect on TB in TB cases vs. LTBI individuals), the latter was found to be significantly affected by the rs7580900 SNP in both comparisons (*p* = 0.0225, OR: 2.76, 95% CI: 1.12--6.84 for LTBI cases vs. healthy controls; *p* = 0.03, OR: 0.38, 95% CI: 0.16--0.95 for TB cases vs. LTBI individuals) (see Figures [S1](#supplementary-material-1){ref-type="supplementary-material"} and [S2](#supplementary-material-1){ref-type="supplementary-material"} in the Supplementary Materials).

We analyzed a block that includes 3 SNPs (rs9061, rs7580900, and rs7580912) in two comparisons (LTBI cases vs. healthy controls and TB cases vs. LTBI individuals) ([Figure 1](#fig1){ref-type="fig"}). We found that the "GAA" (*p* = 0.0037, OR: 1.77, 95% CI: 1.20--2.60), "GGG" (*p* = 0.0009, OR: 2.06, 95% CI: 1.34--3.17), "GGA" (*p* = 0.0009, OR: 2.81, 95% CI: 1.49--5.27), and "GAG" (*p* = 0.0001, OR: 10, 95% CI: 2.36--42.32) haplotypes were associated with disease risk and that the "AGG" haplotype had a protective effect on LTBI (*p* = 0.0254, OR: 0.41, 95% CI: 0.18--0.92) for LTBI cases vs. healthy controls ([Table 5](#tab5){ref-type="table"}). In addition, the "GAA" (*p* = 0.0111, OR: 0.61, 95% CI: 0.42--0.90), "GGG" (*p* = 0.0408, OR: 0.65, 95% CI: 0.43--0.98), "GGA" (*p* = 0.0001, OR: 0.3, 95% CI: 0.16--0.57), and "GAG" (*p* = 0.0001, OR: 0.1, 95% CI: 0.02--0.4) haplotypes showed a protective effect on TB disease for TB patients vs. LTBI individuals ([Table 5](#tab5){ref-type="table"}). These genetic studies suggest that the *SP110* gene plays a key role in modulating susceptibility to latent and active TB infection.

3.4. Association between the *SP110* rs9061 SNP and the TNF*α* Production in LTBI Subjects {#sec3.4}
------------------------------------------------------------------------------------------

TNF*α* plays a crucial role in controlling *Mtb* infection and TB reactivation; however, overproduction of TNF*α* may cause pathology \[[@B35], [@B36]\]. Our previous studies demonstrated that the SP110b protein, which is encoded by the *SP110* gene and whose expression is upregulated by IFNs, downregulates TNF*α* production in monocyte/macrophage cells activated by IFN*γ*, thereby alleviating cell death \[[@B21]\]. This finding indicates that the protein functions as a regulator of proinflammatory cytokines of host immunity contributing to a reduction in tissue damage caused by excessive inflammation \[[@B21]\]. To further investigate the potential association between the *SP110* SNPs and disease status, we next analyzed clinical parameters in the studied subjects. We measured TNF*α* levels in plasma from LTBI individuals who carry the different genotypes of the *SP110* SNPs and demonstrated that the "GA" genotype of rs9061 in LTBI individuals was associated with lower TNF*α* levels in plasma compared to "GG" LTBI subjects ([Figure 2](#fig2){ref-type="fig"}). The TNF*α* levels of healthy controls with both genotypes were undetectable (not shown). These data are in agreement with the protective role of the "GA" genotype of rs9061 in LTBI ([Table 3](#tab3){ref-type="table"}) and further support our recent finding showing that the SP110b protein prevents cell death and tissue damage by downregulating TNF*α* production.

4. Discussion {#sec4}
=============

*SP110* is strongly regulated by IFNs \[[@B17]\], suggesting its possible role in microbial immunity. Although many groups have studied the associations between the gene and TB susceptibility in a variety of populations, these studies show inconclusive results \[[@B22]--[@B29]\]. In our study, we recruited healthy household contacts of TB patients as controls, as these contacts are at a high risk of exposure to *Mtb*. It has been reported that approximately 80-100% of the contacts may have *Mtb* infection, and on average, 20% of them may develop disease \[[@B37]\], indicating that household contacts are at high risk of LTBI and active TB disease. Therefore, examination of this group carries a considerable importance for prevention and control of TB disease. To the best of our knowledge, this is the first study to demonstrate an association between *SP110* and LTBI, and it is the first study of the gene in the Taiwanese population. This work will help clarify the relationship between genetic variation in *SP110* with latent and active TB infection in an Asian population.

Several SNPs (rs7580900, rs7580912, rs9061, rs11556887, and rs2241525) in *SP110* showed an association with susceptibility to LTBI and/or TB disease in our study. In [Table 3](#tab3){ref-type="table"}, we found that genotypes "GG" in rs7580912 (*p* = 0.025, OR: 2.451, 95% CI: 1.12--5.364) and "GG" in rs7580900 (*p* = 0.015, OR: 2.584, 95% CI: 1.208--5.53) were associated with LTBI susceptibility in LTBI cases vs. healthy controls, while the same SNP genotypes exhibited a protective effect on LTBI ("GG" in rs7580912, *p* = 0.02, OR: 0.392, 95% CI: 0.179--0.86; "GG" in rs7580900, *p* = 0.017, OR: 0.392, 95% CI: 0.182--0.848) in TB patients vs. LTBI individuals. In the Haploview analysis, we also found that the haplotype of multiple SNPs "ATGTACGCGA" in the *SP110* gene was significantly associated with LTBI risk (*p* = 0.0225, OR: 2.76, 95% CI: 1.12--6.84) in LTBI cases vs. healthy controls, while the same haplotypes had a protective effect on TB disease (*p* = 0.03, OR: 0.38, 95% CI: 0.16--0.95) in LTBI individuals vs. TB patients (see Figures [S1](#supplementary-material-1){ref-type="supplementary-material"} and [S2](#supplementary-material-1){ref-type="supplementary-material"} in the Supplementary Materials). In addition, 3 SNPs (rs9061, rs7580900, and rs7580912) with the haplotype "GAA" (*p* = 0.0037, OR: 1.77, 95% CI: 1.20--2.60), "GGG" (*p* = 0.0009, OR: 2.06, 95% CI: 1.34--3.17), "GGA" (*p* = 0.0009, OR: 2.81, 95% CI: 1.49--5.27), and "GAG" (*p* = 0.0001, OR: 10, 95% CI: 2.36--42.32) were associated with disease risk in LTBI cases vs. healthy controls, while the same haplotypes showed a protective effect on TB disease for TB patients vs. LTBI individuals (*p* = 0.0111, OR: 0.61, 95% CI: 0.42--0.90 for "GAA"; *p* = 0.0408, OR: 0.65, 95% CI: 0.43--0.98 for "GGG"; *p* = 0.0001, OR: 0.3, 95% CI: 0.16--0.57 for "GGA"; and *p* = 0.0001, OR: 0.1, 95% CI: 0.02--0.4 for "GAG") ([Table 5](#tab5){ref-type="table"}). These results revealed that the same SNP genotypes or haplotypes in the *SP110* gene had opposite effects on the control of susceptibility to LTBI and TB disease, suggesting that the gene may have differential roles in the control of susceptibility to LTBI and TB disease.

SNP rs9061 (G→A) introduces an amino acid change from glutamic acid to lysine at codon position 207 of the SP110 protein. Transforming an acidic amino acid to a basic amino acid may alter the protein structure or posttranslational modification of the SP110 protein leading to better downregulation of TNF*α* production. It has been suggested that the A allele may cause changes in *α*-helices and *β*-sheets in the secondary structure of the SP110 protein compared with the G allele \[[@B38]\]. In addition, we analyzed the SP110 protein using the ELM database (<http://elm.eu.org/>) and found that this amino acid change generates a potential binding motif for the C-terminal ubiquitin-like domain (CTD) of ubiquitin specific protease 7 (USP7), one of the most abundant deubiquitinases \[[@B39]\]. USP7 plays important roles in various biological activities, including cell survival, proliferation, apoptosis, and tumorigenesis \[[@B40], [@B41]\]. As shown in [Figure 2](#fig2){ref-type="fig"}, the data demonstrated an association between the "GA" genotype of rs9061 with lower TNF*α* levels in plasma from LTBI individuals compared to "GG" LTBI subjects. One possible explanation for this result is that SP110 with the "GA" genotype at rs9061 may interact with USP7 and thus is more stable than the SP110 with the "GG" genotype, resulting in a more efficient downregulation of TNF*α* production. However, further functional studies are needed to elucidate the exact effects of SNP rs9061 on the *SP110* gene and disease risk.

Individuals with LTBI, based on a positive result in the TST or the IGRA, usually show no disease symptoms and acquire an effective adaptive immunity. However, a proportion of people with LTBI might reactivate and develop clinical disease. The positive results from these assays indicate an immune response to stimulation by *Mtb* antigens in the LTBI population; however, neither TST nor IGRA can distinguish between LTBI and active TB. In addition, these assays also cannot predict which LTBI cases will progress to active TB \[[@B7]\]. To control and eliminate TB, worldwide TB eradication endeavors have been focused on identifying and treating cases with LTBI. Therefore, our studies identified several SNPs in *SP110* that are significantly associated with controlling susceptibility to LTBI and TB disease and thus may provide novel predictive markers for latent and active TB infection. This study may also yield an improved strategy that can identify persons at increased risk of the disease.

There were some limitations in our study. First, this study dealt with relatively small sample sizes (301, 68, and 278 for TB patients, LTBI cases, and healthy household contacts, respectively). Further large-scale studies are, therefore, needed to validate the predictive value of the *SP110* SNPs identified in this study. Second, the LTBI number of our study group is small, and besides, the results on plasma TNF*α* levels were analyzed from groups with even smaller sample sizes; therefore, the difference in TNF*α* levels in plasma of LTBI cases with two genotypes may be underestimated and should be verified in a different population. In addition, the analysis of TNF*α* levels in plasma of active TB patients with the different genotypes is in progress. The result may help support our finding in LTBI individuals and clarify the potential association between the *SP110* SNPs and disease status.

5. Conclusions {#sec5}
==============

The results suggest that the *SP110* variants have a role in controlling genetic susceptibility to latent and active TB infection in humans. To the best of our knowledge, this is the first report demonstrating associations of polymorphisms in *SP110* with LTBI susceptibility. Additionally, we provide evidence that the *SP110* rs9061 SNP is associated with plasma TNF*α* levels in LTBI individuals. These data suggest that the identified *SP110* SNPs may serve as a biomarker for latent and active TB infection in Taiwan.
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###### 

Table S1: primers for genotype analysis for SP110. Figure S1: association of SP110 SNP haplotypes with LTBI risk in LTBI cases vs. healthy controls. (a) Haplotype block map for SP110 with 10 SNPs. (b) Association of haplotype frequencies with LTBI risk in LTBI cases and healthy controls. Figure S2: association of SP110 SNP haplotypes with TB risk in TB cases vs. LTBI individuals. (a) Haplotype block map for SP110 with 10 SNPs. (b) Association of haplotype frequencies with TB risk in TB cases vs. LTBI individuals. Figure S3: association of SP110 SNP haplotypes with TB risk in TB cases vs. healthy controls. (a) Haplotype block map for SP110 with 10 SNPs. (b) Association of haplotype frequencies with TB risk in TB cases and healthy controls.

###### 

Click here for additional data file.

![Haplotype block maps for *SP110* with 3 SNPs (rs9061, rs7580900, and rs7580912). The haplotype blocks were analyzed in LTBI cases vs. healthy controls (a) and TB cases vs. LTBI individuals (b), respectively.](DM2018-4687380.001){#fig1}

![Association between the *SP110* rs9061 SNP and the TNF levels in plasma of LTBI subjects. The TNF production was determined in plasma samples from LTBI cases carrying the different genotypes of the rs9061 SNP by a MAGPIX instrument with a MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel I kit. Sample numbers are 14 for "GG" and 8 for "GA" genotypes, respectively. Statistical significance was calculated using a two-tailed unpaired *t*-test. ^∗^ *p* \< 0.05.](DM2018-4687380.002){#fig2}

###### 

Demographic characteristics of TB patients, LTBI cases, and healthy controls in this study.

  Group    Number   Age (years)                            
  -------- -------- ------------- ---------- ------------- -----------
  Health   278      92 (33)       186 (67)   47.1 ± 17.3   15.2-93.9
  LTBI     68       35 (51)       33 (49)    46.9 ± 17.7   19.5-86.5
  TB       301      202 (67)      99 (33)    63.1 ± 19.9   19.4-98.7

###### 

Allele frequencies of polymorphisms in *SP110* in TB patients, LTBI cases, and healthy controls.

###### 

\(a\) Allele frequencies in LTBI cases and healthy controls and odds ratio estimates for LTBI

  ------------------------------------------------------------------------------------------------------------------------
  SNP ID       Position^1^   Location^2^    HWEp     Alleles   LTBI\        Health\      OR\                *p* value
                                                               *n* (%)      *n* (%)      (95% CI)           
  ------------ ------------- -------------- -------- --------- ------------ ------------ ------------------ --------------
  rs7580912    230216690     Intron 2-3     0.1113   A         48 (40)      165 (30.4)   1.52 (1.01-2.39)   *0.0426*

  G            72 (60)       377 (69.6)                                                                     

  rs7580900    230216669     Intron 2-3     0.5446   A         67 (52.3)    214 (39.5)   1.68 (1.14-2.48)   *0.008*

  G            61 (47.7)     328 (60.5)                                                                     

  rs11556887   230212961     Exon 4         0.0593   C         113 (88.3)   476 (87.8)   0.96 (0.53-1.74)   0.8862

  T            15 (11.7)     66 (12.2)                                                                      

  rs9061       230212395     Exon 5         0.1272   G         118 (90.8)   427 (79.4)   0.39 (0.21-0.73)   *0.0026* ^∗^

  A            12 (9.2)      111 (20.6)                                                                     

  rs3820974    230211574     Intron 5-6     0.8257   C         93 (71.5)    366 (67.5)   0.83 (0.54-1.26)   0.3774

  A            37 (28.5)     176 (32.5)                                                                     

  rs1365776    230207994     Exon 8         0.4341   A         111 (91)     479 (89.7)   0.86 (0.44-1.70)   0.6708

  G            11 (9)        55 (10.3)                                                                      

  rs41309108   230201006     Intron 9-10    0.0333   T         105 (80.8)   415 (76.6)   0.78 (0.48-1.26)   0.3039

  A            25 (19.2)     127 (23.4)                                                                     

  rs2241525    230178086     Intron 13-14   0.451    G         30 (24.6)    93 (17.4)    1.55 (0.97-2.47)   0.067

  A            92 (75.4)     441 (82.6)                                                                     

  rs1135791    230177560     Exon 14        0.4826   T         107 (89.2)   472 (87.4)   0.76 (0.41-1.43)   0.5952

  C            13 (10.8)     68 (12.6)                                                                      

  rs10498244   230173117     Intron 14-15   0.5064   A         95 (89.6)    459 (86.6)   0.75 (0.38-1.47)   0.3972

  G            11 (10.4)     71 (13.4)                                                                      
  ------------------------------------------------------------------------------------------------------------------------

^1^NCBI Reference Sequence: NC_000002.12. ^2^Based on SP110c (NCBI Reference Sequence: NM_080424.2). HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval; ORs are adjusted for gender. The significant ORs are shown in italic. ^∗^OR remains significant after Bonferroni correction.

###### 

\(b\) Allele frequencies in TB patients and healthy controls and odds ratio estimates for TB

  ---------------------------------------------------------------------------------------------------------------------
  SNP ID       Position^1^   Location^2^    HWEp     Alleles   LTBI\        Health\      OR\                *p* value
                                                               *n* (%)      *n* (%)      (95% CI)           
  ------------ ------------- -------------- -------- --------- ------------ ------------ ------------------ -----------
  rs7580912    230216690     Intron 2-3     0.9813   A         201 (33.6)   165 (30.4)   1.16 (0.91-1.49)   0.2524

  G            397 (66.4)    377 (69.6)                                                                     

  rs7580900    230216669     Intron 2-3     0.8338   A         251 (42)     214 (39.5)   1.11 (0.88-1.41)   0.393

  G            347 (58)      328 (60.5)                                                                     

  rs11556887   230212961     Exon 4         0.7296   C         543 (90.8)   476 (87.8)   0.73 (0.50-1.07)   0.1028

  T            55 (9.2)      66 (12.2)                                                                      

  rs9061       230212395     Exon 5         0.0162   G         485 (81.6)   427 (79.4)   0.86 (0.64-1.16)   0.3326

  A            109 (18.4)    111 (20.6)                                                                     

  rs3820974    230211574     Intron 5-6     0.9602   C         195 (32.6)   17 (32.5)    1.01 (0.79-1.29)   0.9609

  A            403 (67.4)    366 (67.5)                                                                     

  rs1365776    230207994     Exon 8         0.0396   A         67 (11.2)    55 (10.3)    1.10 (0.75-1.59)   0.6242

  G            531 (88.8)    479 (89.7)                                                                     

  rs41309108   230201006     Intron 9-10    0.0393   T         463 (77.4)   415 (76.6)   0.95 (0.72-1.26)   0.7314

  A            135 (22.6)    127 (23.4)                                                                     

  rs2241525    230178086     Intron 13-14   0.102    G         495 (83.6)   441 (82.6)   0.93 (0.68-1.27)   0.6447

  A            97 (16.4)     93 (17.4)                                                                      

  rs1135791    230177560     Exon 14        0.3517   T         92 (15.4)    68 (12.6)    1.28 (0.92-1.80)   0.176

  C            506 (84.6)    472 (87.4)                                                                     

  rs10498244   230173117     Intron 14-15   0.5808   A         88 (14.7)    71 (13.4)    1.13 (0.81-1.59)   0.525

  G            510 (85.3)    459 (86.6)                                                                     
  ---------------------------------------------------------------------------------------------------------------------

^1^NCBI Reference Sequence: NC_000002.12. ^2^Based on SP110c (NCBI Reference Sequence: NM_080424.2). HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval; ORs are adjusted for gender.

###### 

\(c\) Allele frequencies in TB patients and LTBI cases and odds ratio estimates for TB

  ---------------------------------------------------------------------------------------------------------------------
  SNP ID       Position^1^   Location^2^    HWEp     Alleles   LTBI\        Health\      OR\                *p* value
                                                               *n* (%)      *n* (%)      (95% CI)           
  ------------ ------------- -------------- -------- --------- ------------ ------------ ------------------ -----------
  rs7580912    230216690     Intron 2-3     0.7351   A         397 (66.4)   72 (60)      0.76 (0.51-1.14)   0.1797

  G            201 (33.6)    48 (40)                                                                        

  rs7580900    230216669     Intron 2-3     0.9968   A         347 (58)     61 (47.7)    0.66 (0.45-0.97)   *0.0319*

  G            251 (42)      67 (52.3)                                                                      

  rs11556887   230212961     Exon 4         0.8656   C         543 (90.8)   113 (88.3)   0.76 (0.42-1.40)   0.3804

  T            55 (9.2)      15 (11.7)                                                                      

  rs9061       230212395     Exon 5         0.0995   G         109 (18.4)   12 (9.2)     2.21 (1.18-4.15)   *0.0116*

  A            485 (81.6)    118 (90.8)                                                                     

  rs3820974    230211574     Intron 5-6     0.8727   C         195 (32.6)   37 (28.5)    1.22 (0.80-1.85)   0.3577

  A            403 (67.4)    93 (71.5)                                                                      

  rs1365776    230207994     Exon 8         0.028    A         67 (11.2)    11 (9)       1.27 (0.65-2.49)   0.4786

  G            531 (88.8)    111 (91)                                                                       

  rs41309108   230201006     Intron 9-10    0.2174   T         135 (22.6)   25 (19.2)    1.22 (0.76-1.97)   0.4039

  A            463 (77.4)    105 (80.8)                                                                     

  rs2241525    230178086     Intron 13-14   0.1275   G         495 (83.6)   92 (75.4)    0.60 (0.38-0.96)   *0.0309*

  A            97 (16.4)     30 (24.6)                                                                      

  rs1135791    230177560     Exon 14        0.3733   T         92 (15.4)    13 (10.8)    1.50 (0.81-2.77)   0.1979

  C            506 (84.6)    107 (89.2)                                                                     

  rs10498244   230173117     Intron 14-15   0.8897   A         88 (14.7)    11 (10.4)    1.49 (0.77-2.89)   0.2363

  G            510 (85.3)    95 (89.6)                                                                      
  ---------------------------------------------------------------------------------------------------------------------

^1^NCBI Reference Sequence: NC_000002.12. ^2^Based on SP110c (NCBI Reference Sequence: NM_080424.2). HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval; ORs are adjusted for gender. The significant ORs are shown in italic.

###### 

Association analyses of *SP110* SNP genotypes with LTBI and TB susceptibility.

###### 

\(a\) Association between *SP110* SNP genotypes and LTBI risk in LTBI cases vs. healthy controls

  SNP ID       Genotypes   Health no. (%)   LTBI no. (%)                OR (95% CI)   *p* value
  ------------ ----------- ---------------- --------------------------- ------------- -----------
  rs7580912    AA          134 (49)         26 (43)                     Ref           ---
  GA           111 (41)    20 (33)          0.884 (0.464-1.686)         0.709         
  GG           27 (10)     14 (23)          2.451 (1.12-5.364)          *0.025*       
  rs7580900    AA          100 (37)         16 (25)                     Ref           ---
  GA           128 (47)    29 (45)          1.403 (0.716-2.749)         0.324         
  GG           43 (16)     19 (30)          2.584 (1.208-5.53)          *0.015*       
  rs11556887   CC          206 (76)         49 (77)                     Ref           ---
  CT           64 (24)     15 (23)          0.982 (0.513-1.882)         0.957         
  TT           1 (0.4)     0 (0)            \<0.001 (\<0.001-999.999)   0.967         
  rs9061       GG          177 (65)         54 (82)                     Ref           ---
  AA           16 (6)      0 (0)            \<0.001 (\<0.001-999.999)   0.901         
  GA           79 (29)     12 (18)          0.494 (0.239-0.981)         ***0.044***   
  rs3820974    CC          125 (46)         34 (52)                     Ref           ---
  AA           29 (11)     6 (9)            0.712 (0.269-1.886)         0.494         
  CA           118 (43)    25 (38)          0.703 (0.391-1.264)         0.239         
  rs1365776    AA          217 (81)         52 (83)                     Ref           ---
  GA           47 (18)     10 (16)          0.757 (0.345-1.66)          0.487         
  GG           4 (1)       1 (1)            1.212 (0.129-11.39)         0.867         
  rs41309108   TT          153 (56)         41 (63)                     Ref           ---
  AA           10 (4)      1 (1)            0.395 (0.048-3.248)         0.387         
  TA           109 (40)    23 (35)          0.768 (0.433-1.362)         0.367         
  rs2241525    GG          186 (69)         36 (58)                     Ref           ---
  AA           10 (4)      4 (7)            1.984 (0.579-6.802)         0.276         
  GA           75 (28)     22 (35)          1.509 (0.828-2.75)          0.179         
  rs1135791    TT          206 (75)         48 (79)                     Ref           ---
  CC           3 (1)       0 (0)            \<0.001 (\<0.001-999.999)   0.943         
  CT           64          13 (21)          0.86 (0.434-1.703)          0.667         
  rs10498244   AA          199 (75)         44 (83)                     Ref           ---
  AG           61 (23)     7 (13)           0.523 (0.223-1.223)         0.135         
  GG           5 (2)       2 (4)            1.9 (0.354-10.203)          0.454         

OR: odds ratio; CI: confidence interval; ORs are adjusted for gender. The significant ORs are shown in italic.

###### 

\(b\) Association between *SP110* SNP genotypes and TB risk in TB patients vs. LTBI cases

  SNP ID       Genotypes   Health no. (%)   LTBI No. (%)                    OR (95% CI)   *p* value
  ------------ ----------- ---------------- ------------------------------- ------------- -----------
  rs7580912    AA          26 (43)          129 (43)                        Ref           ---
  GA           20 (33)     139 (47)         1.377 (0.731-2.595)             0.322         
  GG           14 (23)     31 (10)          0.392 (0.179-0.86)              *0.02*        
  rs7580900    AA          16 (25)          98 (33)                         Ref           ---
  GA           29 (45)     151 (50)         0.863 (0.444-1.878)             0.664         
  GG           19 (30)     50 (17)          0.392 (0.182-0.848)             *0.017*       
  rs11556887   CC          49 (77)          248 (83)                        Ref           ---
  CT           15 (23)     47 (16)          0.628 (0.324-1.219)             0.169         
  TT           0 (0)       4 (1)            \>999.999 (\<0.001-\>999.999)   0.988         
  rs9061       GG          54 (82)          203 (68)                        Ref           ---
  AA           0 (0)       15 (5)           \>999.999 (\<0.001-\>999.999)   0.974         
  GA           12 (18)     79 (27)          1.831 (0.924-3.627)             0.083         
  rs3820974    CC          34 (52)          136 (45)                        Ref           ---
  AA           6 (9)       32 (11)          1.261 (0.483-3.293)             0.637         
  CA           25 (38)     131 (44)         1.31 (0.739-2.323)              0.356         
  rs1365776    AA          52 (83)          240 (80)                        Ref           ---
  GA           10 (16)     51 (17)          1.264 (0.58-2.753)              0.556         
  GG           1 (1)       8 (3)            2.028 (0.244-16.888)            0.513         
  rs41309108   TT          41 (63)          176 (59)                        Ref           ---
  AA           1 (1)       12 (4)           2.401 (0.3-19.219)              0.409         
  TA           23 (35)     111 (37)         1.096 (0.621-1.932)             0.753         
  rs2241525    GG          36 (58)          211 (71)                        Ref           ---
  AA           4 (7)       12 (4)           0.47 (0.142-1.562)              0.218         
  GA           22 (35)     73 (25)          0.564 (0.31-1.026)              0.061         
  rs1135791    TT          48 (79)          212 (71)                        Ref           ---
  CC           0 (0)       5 (2)            \>999.999 (\<0.001-\>999.999)   0.986         
  CT           13 (21)     82 (27)          1.33 (0.68-2.602)               0.404         
  rs10498244   AA          44 (83)          215 (72)                        Ref           ---
  AG           7 (13)      80 (27)          2.137 (0.917-4.981)             0.079         
  GG           2 (4)       4 (1)            0.441 (0.074-2.62)              0.368         

OR: odds ratio; CI: confidence interval; ORs are adjusted for gender. The significant ORs are shown in italic.

###### 

\(c\) Association between *SP110* SNP genotypes and TB risk in TB patients vs. healthy controls

  SNP ID       Genotypes   Health no. (%)   LTBI no. (%)           OR (95% CI)   *p* value
  ------------ ----------- ---------------- ---------------------- ------------- -----------
  rs7580912    AA          134 (49)         129 (43)               Ref           ---
  GA           111 (41)    139 (47)         1.258 (0.869-1.822)    0.224         
  GG           27 (10)     31 (10)          0.877 (0.474-1.622)    0.676         
  rs7580900    AA          100 (37)         98 (33)                Ref           ---
  GA           128 (47)    151 (50)         1.258 (0.851-1.86)     0.249         
  GG           43 (16)     50 (17)          1.023 (0.601-1.74)     0.934         
  rs11556887   CC          206 (76)         248 (83)               Ref           ---
  CT           64 (23.6)   47 (16)          0.626 (0.401-0.976)    *0.039*       
  TT           1 (0.4)     4 (1)            2.387 (0.243-23.458)   0.456         
  rs9061       GG          176 (65)         203 (68)               Ref           ---
  AA           17 (6)      15 (5)           0.792 (0.36-1.742)     0.561         
  GA           79 (29)     79 (27)          0.886 (0.597-1.313)    0.546         
  rs3820974    CC          125 (46)         136 (45)               Ref           ---
  AA           29 (11)     32 (11)          0.871 (0.473-1.603)    0.657         
  CA           118 (43)    131 (44)         0.942 (0.651-1.363)    0.749         
  rs1365776    AA          217 (81)         240 (80)               Ref           ---
  GA           47 (18)     51 (17)          0.931 (0.582-1.489)    0.767         
  GG           4 (2)       8 (3)            2.291 (0.631-8.322)    0.208         
  rs41309108   TT          153 (56)         176 (59)               Ref           ---
  AA           9 (3)       12 (4)           0.982 (0.382-2.527)    0.971         
  TA           109 (40)    111 (37)         0.852 (0.593-1.225)    0.387         
  rs2241525    GG          186 (69)         211 (71)               Ref           ---
  AA           10 (3)      12 (4)           1.004 (0.402-2.505)    0.994         
  GA           75 (28)     73 (25)          0.85 (0.569-1.268)     0.425         
  rs1135791    TT          206 (75)         212 (71)               Ref           ---
  CC           3 (1)       5 (2)            1.681 (0.371-7.617)    0.5           
  CT           64 (24)     82 (27)          1.177 (0.788-1.76)     0.426         
  rs10498244   AA          199 (75)         215 (72)               Ref           ---
  AG           61 (23)     80 (27)          1.185 (0.787-1.785)    0.417         
  GG           5 (2)       4 (1)            0.774 (0.191-3.133)    0.719         

OR: odds ratio; CI: confidence interval; ORs are adjusted for gender. The significant ORs are shown in italic.

###### 

Association analyses of *SP110* SNP genotypes with LTBI and TB susceptibility in various inheritance models.

###### 

\(a\) Association analyses of *SP110* SNP genotypes in an additive model

  SNP ID       TB vs. health      TB vs. LTBI   LTBI vs. health                                  
  ------------ ------------------ ------------- ------------------ ---------- ------------------ ----------
  rs9061       0.89 (0.66,1.2)    0.4382        2.17 (1.16,4.06)   *0.015*    0.41 (0.22,0.78)   *0.0059*
  rs7580900    1.07 (0.83,1.38)   0.5839        0.64 (0.43,0.95)   *0.0261*   1.62 (1.1,2.39)    *0.0147*
  rs3820974    0.94 (0.72,1.23)   0.6661        1.2 (0.79,1.82)    0.4009     0.79 (0.51,1.21)   0.2761
  rs41309108   0.9 (0.66,1.22)    0.4917        1.2 (0.73,1.97)    0.4824     0.73 (0.44,1.23)   0.2366
  rs7580912    1.05 (0.8,1.37)    0.7307        0.74 (0.49,1.1)    0.1387     1.4 (0.94,2.08)    0.0992
  rs1135791    1.2 (0.83,1.73)    0.3242        1.46 (0.77,2.77)   0.2444     0.81 (0.42,1.56)   0.525
  rs1365776    1.1 (0.75,1.62)    0.6153        1.32 (0.7,2.5)     0.3933     0.84 (0.43,1.65)   0.6133
  rs10498244   1.1 (0.77,1.59)    0.5919        1.4 (0.71,2.73)    0.3303     0.77 (0.4,1.5)     0.4457
  rs2241525    0.91 (0.66,1.25)   0.5681        0.62 (0.4,0.98)    *0.0407*   1.46 (0.92,2.32)   0.1102
  rs11556887   0.72 (0.48,1.08)   0.1155        0.75 (0.41,1.39)   0.362      0.96 (0.5,1.81)    0.8916

OR: odds ratio; CI: confidence interval; ORs are adjusted for gender. The significant ORs are shown in italic.

###### 

\(b\) Association analyses of *SP110* SNP genotypes in a dominant model

  SNP ID       TB vs. health      TB vs. LTBI   LTBI vs. health                                      
  ------------ ------------------ ------------- ------------------ -------------- ------------------ ----------
  rs9061       0.87 (0.6,1.26)    0.4646        2.14 (1.09,4.22)   *0.0273*       0.42 (0.21,0.82)   *0.0112*
  rs7580900    1.22 (0.84,1.76)   0.2929        0.68 (0.37,1.27)   0.2276         1.74 (0.93,3.24)   0.083
  rs3820974    0.93 (0.65,1.32)   0.6879        1.3 (0.76,2.24)    0.3378         0.71 (0.41,1.23)   0.2193
  rs41309108   0.86 (0.6,1.23)    0.4092        1.15 (0.66,2.01)   0.6191         0.74 (0.42,1.3)    0.2917
  rs7580912    1.18 (0.83,1.68)   0.3571        0.98 (0.55,1.72)   0.9312         1.2 (0.68,2.12)    0.5388
  rs1135791    1.2 (0.81,1.78)    0.3678        1.41 (0.72,2.75)   0.3146         0.83 (0.42,1.64)   0.5948
  rs1365776    1.03 (0.66,1.6)    0.9033        1.34 (0.64,2.82)   0.4408         0.79 (0.37,1.67)   0.5353
  rs10498244   1.15 (0.77,1.72)   0.4807        1.75 (0.81,3.78)   0.1536         0.63 (0.29,1.35)   0.2341
  rs2241525    0.87 (0.59,1.27)   0.4667        0.55 (0.31,0.97)   ***0.0389***   1.57 (0.88,2.78)   0.1239
  rs11556887   0.66 (0.43,1.02)   0.0609        0.67 (0.35,1.3)    0.2363         0.97 (0.51,1.86)   0.9282

OR: odds ratio; CI: confidence interval; ORs are adjusted for gender. The significant ORs are shown in italic.

###### 

\(c\) Association analyses of *SP110* SNP genotypes in a recessive model

  SNP ID       TB vs. health      TB vs. LTBI   LTBI vs. health                                    
  ------------ ------------------ ------------- ------------------- ---------- ------------------- --------------
  rs9061       0.82 (0.38,1.78)   0.6227        ---                 ---        ---                 ---
  rs7580900    0.92 (0.57,1.48)   0.737         0.45 (0.24,0.84)    *0.0117*   2.13 (1.13,4.03)    *0.0195* ^∗^
  rs3820974    0.92 (0.52,1.62)   0.7796        1.13 (0.45,2.83)    0.8018     0.84 (0.33,2.15)    0.7209
  rs41309108   1.05 (0.41,2.66)   0.9241        2.35 (0.3,18.52)    0.4186     0.43 (0.05,3.55)    0.437
  rs7580912    0.79 (0.44,1.42)   0.4367        0.35 (0.17,0.72)    *0.0043*   2.49 (1.2,5.18)     *0.0142* ^∗^
  rs1135791    1.63 (0.36,7.51)   0.5284        ---                 ---        ---                 ---
  rs1365776    2.25 (0.63,8.05)   0.2129        1.94 (0.23,16.11)   0.5375     1.24 (0.13,11.51)   0.8504
  rs10498244   0.74 (0.18,3.05)   0.6804        0.38 (0.06,2.23)    0.2844     2.27 (0.42,12.19)   0.3385
  rs2241525    1.05 (0.42,2.6)    0.9172        0.56 (0.17,1.83)    0.3374     1.73 (0.52,5.81)    0.3747
  rs11556887   2.63 (0.27,25.7)   0.4064        ---                 ---        ---                 ---

OR: odds ratio; CI: confidence interval; ORs are adjusted for gender. The significant ORs are shown in italic. ^∗^ORs remain significant after false discovery rate (FDR) correction.

###### 

Association of the haplotype frequencies of *SP110* SNPs with 3 SNPs (rs9061, rs7580900, and rs7580912) with LTBI and TB susceptibility.

###### 

\(a\) Association of haplotype frequencies with LTBI risk in LTBI cases and healthy controls

  Haplotypes   Frequencies   Chi-square   OR (95% CI)   *p* value            
  ------------ ------------- ------------ ------------- -------------------- --------------
  GAA          0.417         0.558        8.417         1.77 (1.20-2.60)     *0.0037*
  GGG          0.310         0.179        11.048        2.06 (1.34-3.17)     *9.00E − 04*
  AGG          0.053         0.120        4.997         0.41 (0.18-0.92)     *0.0254*
  GGA          0.134         0.052        10.99         2.81 (1.49-5.27)     *9.00E − 04*
  AGA          0.021         0.043        1.429         0.47 (0.13-1.68)     0.232
  AAA          0.019         0.042        1.579         0.44 (0.12-1.65)     0.209
  GAG          0.047         0.005        14.5          10.00 (2.36-42.32)   *1.00E − 04*

OR: odds ratio; CI: confidence interval; ORs are adjusted for gender. The significant ORs are shown in italic.

###### 

\(b\) Association of haplotype frequencies with TB risk in TB cases vs. LTBI individuals

  Haplotypes   Frequencies   Chi-square   OR (95% CI)   *p* value          
  ------------ ------------- ------------ ------------- ------------------ ----------
  GAA          0.540         0.417        6.445         0.61 (0.42-0.90)   *0.0111*
  GGG          0.228         0.313        4.184         0.65 (0.43-0.98)   *0.0408*
  AGG          0.103         0.053        3.191         2.05 (0.91-4.62)   0.074
  GGA          0.043         0.130        14.591        0.30 (0.16-0.57)   *0.0001*
  AGA          0.045         0.021        1.564         2.16 (0.62-7.49)   0.211
  AAA          0.035         0.018        0.993         1.95 (0.51-7.53)   0.3191
  GAG          0.005         0.047        16.031        0.10 (0.02-0.40)   *0.0001*

OR: odds ratio; CI: confidence interval; ORs are adjusted for gender. The significant ORs are shown in italic.

[^1]: Academic Editor: Frank Tacke
